SORCS2 Gene

📖 Wiki Page

gene2710 wordssynced 2026-04-02

| Property | Value |
|----------|-------|
| Gene Symbol | SORCS2 |
| Full Name | Sortilin-Related VPS10 Domain Containing Receptor 2 |
| Chromosomal Location | 4p16.1 |
| NCBI Gene ID | 22999 |
| OMIM ID | 606284 |
| Ensembl ID | ENSG00000145945 |
| UniProt ID | Q9Y6I9 |
| Encoded Protein | Sortilin-related receptor 2 |
| Associated Diseases | Alzheimer's Disease (risk factor), Parkinson's Disease (risk factor), ADHD |

</div>

Overview

SORCS2 (Sortilin-Related VPS10 Domain Containing Receptor 2) encodes a member of the sortilin family of VPS10P domain receptors. This neuronal trafficking receptor plays critical roles in protein sorting, neurotrophin signaling, and synaptic function. Genetic variants in SORCS2 have been implicated in Alzheimer's disease, Parkinson's disease, and attention-deficit/hyperactivity disorder (ADHD), positioning it as a gene of interest in neurodegeneration research[@reitz2013][@lane2016].

The SORCS (Sortilin-Related VPS10 Domain Containing) family consists of three related receptors—SORCS1, SORCS2, and SORCS3—each with distinct expression patterns and functional properties. While SORCS1 has received significant attention in Alzheimer's disease research, SORCS2 has emerged as an independent modulator of neuronal function with unique roles in amyloid precursor protein (APP) trafficking and dopamine signaling.

Gene Structure and Evolution

Genomic Organization

...

</div>

Overview

Gene Structure and Evolution

Genomic Organization

The SORCS2 gene spans approximately 63 kb on chromosome 4p16.1, containing 24 exons that encode a type I transmembrane protein of 835 amino acids. The gene structure shares conserved features with other SORCS family members, including the characteristic VPS10P domain in the extracellular region.

| Domain | Position | Length (aa) | Function |
|--------|----------|-------------|----------|
| Signal peptide | 1-23 | 23 | Secretory pathway targeting |
| VPS10P domain | 24-661 | 638 | Ligand binding |
| Transmembrane | 709-731 | 23 | Membrane anchoring |
| Cytoplasmic tail | 732-835 | 104 | Trafficking signals |

Evolutionary Conservation

SORCS2 shows high conservation among mammalian species, with orthologs identified in rodents, primates, and other vertebrates. The VPS10P domain is particularly conserved, reflecting its essential role in ligand binding and receptor function.

Protein Function and Trafficking

VPS10P Domain Architecture

The VPS10P (vacuolar protein sorting 10 protein) domain constitutes the extracellular ligand-binding module of SORCS2. This domain shares structural homology with other members of the mammalian VPS10P receptor family, including sortilin, SORCS1, and SORCS3.

The VPS10P domain mediates binding to multiple ligands:

Neurotrophins — NGF (nerve growth factor), BDNF (brain-derived neurotrophic factor), NT-3, NT-4
APP and derivatives — Amyloid precursor protein and its proteolytic fragments
Receptor ligands — p75 neurotrophin receptor (p75NTR), sortilin

Intracellular Trafficking

SORCS2 follows the canonical secretory pathway:

Mermaid diagram (expand to render)

The cytoplasmic tail contains trafficking motifs that direct subcellular localization:

Di-leucine motif (DDQSDL) — Mediates endosomal sorting
Tyrosine-based motif (YXXPhi) — Participates in polarized trafficking

Ligand Interactions

Neurotrophin Trafficking

SORCS2 plays a critical role in neurotrophin trafficking within neurons[@mukherjee2019]:

BDNF trafficking — SORCS2 binds pro-BDNF and mature BDNF, directing their intracellular routing

NGF sorting — Contributes to NGF transport in sympathetic and sensory neurons

Sortilin cooperation — Forms heteromeric complexes with sortilin for coordinated trafficking

The p75NTR interaction is particularly relevant to neurodegeneration[@offe2006]. SORCS2 can bind p75NTR and modulate its signaling function, potentially influencing neuronal survival pathways.

APP Trafficking

Recent research has identified SORCS2 as a regulator of APP processing[@morganti2020][@butler2018]:

| Process | SORCS2 Effect | AD Relevance |
|---------|---------------|--------------|
| APP vesicular transport | Modulates APP delivery to processing compartments | Alters Aβ production |
| BACE access | Affects β-secretase cleavage site availability | Influences amyloidogenesis |
| Aβ secretion | Regulates Aβ release from neurons | Impacts plaque formation |
| Amyloid plaque burden | SORCS2 knockout shows altered plaque load | Validates in vivo role |

Expression Patterns

Brain Regional Distribution

SORCS2 exhibits brain-enriched expression with regional specificity:

| Brain Region | Expression Level | Cell Type |
|--------------|------------------|-----------|
| Cortex (frontal) | High | Pyramidal neurons |
| Hippocampus | High | CA1-CA3 pyramidal cells, dentate gyrus granule cells |
| Basal ganglia | Moderate-High | Medium spiny neurons |
| Hypothalamus | High | Paraventricular nucleus neurons |
| Cerebellum | Low-Moderate | Purkinje cells |
| Substantia nigra | Moderate | Dopaminergic neurons |

The enrichment in hippocampus and cortex aligns with AD-relevant brain regions, while basal ganglia and substantia nigra expression implicates PD-related pathways.

Cell Type Specificity

SORCS2 expression is primarily neuronal:

Excitatory neurons — High expression in pyramidal neurons
Inhibitory neurons — Moderate expression in interneurons
Glial cells — Minimal expression in astrocytes and microglia

Subcellular Localization

| Compartment | Function |
|-------------|----------|
| Endoplasmic reticulum | Newly synthesized receptor |
| Golgi apparatus | Processing and sorting |
| Early endosomes | Primary sorting hub |
| Late endosomes/lysosomes | Degradation pathway |
| Plasma membrane | Signaling platform |
| Synaptic vesicles | Activity-dependent release |

Disease Associations

Alzheimer's Disease

SORCS2 has been implicated in AD through multiple lines of evidence[@reitz2013][@gao2022]:

Genetic Association

GWAS signals — SORCS2 shows modest but reproducible association with late-onset AD risk
Rare variants — Exome sequencing studies have identified rare SORCS2 variants that may increase AD risk
Gene-gene interactions — Epistatic effects with SORCS1 and other trafficking genes

Expression Studies

AD brain — Altered SORCS2 expression in cortex and hippocampus
Cellular models — SORCS2 knockdown affects APP processing
Animal models — SORCS2 knockout mice show changes in amyloid pathology

Mechanistic Links

SORCS2 influences AD through:

APP trafficking — Modulates APP delivery to amyloidogenic processing compartments

Aβ secretion — Affects the release of Aβ40 and Aβ42 peptides

Synaptic function — Regulates synaptic protein trafficking critical for cognition

Neurotrophin signaling — BDNF trafficking defects may contribute to synaptic loss

The interaction with p75NTR is particularly relevant, as this receptor can mediate amyloid-induced neuronal death.

Parkinson's Disease

SORCS2 variants have been associated with PD risk[@petry2019]:

| Evidence Type | Finding |
|---------------|---------|
| GWAS | Modest association with PD risk |
| Exome sequencing | Rare variants in PD cases |
| Expression | Altered in PD substantia nigra |
| Pathway | Dopaminergic neuron trafficking |

The dopaminergic pathway involvement is key:

Dopamine transporter (DAT) — SORCS2 interacts with DAT trafficking machinery
Dopamine receptor sorting — Regulates D1/D2 receptor surface expression
LRRK2 interaction — Potential crosstalk with LRRK2 pathway

Attention-Deficit/Hyperactivity Disorder (ADHD)

SORCS2 was originally identified as an ADHD risk gene[@zhang2014]:

GWAS signals — Association with ADHD in pediatric cohorts
Brain function — SORCS2 variants affect dopaminergic signaling
Clinical phenotypes — Links to attention and impulse control

The ADHD association may reflect SORCS2's role in:

Dopamine transporter function
Prefrontal cortical development
Attention circuit formation

Signaling Pathways

Neurotrophin Signaling

SORCS2 modulates neurotrophin signaling through multiple mechanisms:

Mermaid diagram (expand to render)

APP Processing

SORCS2 influences amyloidogenic processing:

| Step | Mechanism |
|------|-----------|
| APP transport | Directs APP to secretase-containing compartments |
| BACE access | Modulates spatial proximity to β-secretase |
| γ-secretase processing | Affects Aβ peptide generation |
| Aβ secretion | Controls extracellular Aβ release |

Therapeutic Implications

Targeting SORCS2

SORCS2 represents a potential therapeutic target:

| Strategy | Approach | Status |
|----------|----------|--------|
| Small molecules | SORCS2 agonists/antagonists | Preclinical |
| Peptide blockers | Interfere with pathogenic interactions | Discovery |
| Gene therapy | Modulate SORCS2 expression | Research |
| Antibody therapy | Target extracellular domain | Research |

Biomarker Potential

SORCS2 levels may serve as biomarkers:

CSF SORCS2 — Potential disease state indicator
Blood expression — Peripheral biomarker development

Research Directions

Unanswered Questions

How exactly does SORCS2 modulate APP processing?

What determines ligand specificity in different brain regions?

Can SORCS2 be targeted therapeutically without adverse effects?

What is the relationship between SORCS2 and other AD risk genes?

How do SORCS2 rare variants contribute to disease pathogenesis?

What is the role of SORCS2 in tau pathology propagation?

Ongoing Research

Single-cell studies of SORCS2 expression in AD brain
Structural studies of SORCS2-ligand interactions
iPSC models with SORCS2 variants
In vivo imaging of SORCS2 trafficking
CRISPR screens identifying SORCS2-dependent pathways

Protein Structure and Biochemistry

Domain Architecture

SORCS2 contains multiple functional domains that mediate its diverse cellular functions:

Mermaid diagram (expand to render)

VPS10P Domain Details

The VPS10P domain is the signature feature of the SORCS family:

| Feature | Description |
|---------|--------------|
| N-terminal propeptide | Cleaved in Golgi, activates receptor |
| 10 conserved cysteine residues | Form disulfide bonds |
| Ligand binding pocket | Multiple binding sites |
| Homodimerization interface | May form functional dimers |

Cytoplasmic Tail Motifs

The intracellular domain contains critical trafficking signals:

Di-leucine motif (D/EXXXL/L) — Directs sorting to endosomes and lysosomes

Tyrosine-based motif (YXXΦ) — Mediates clathrin-dependent trafficking

PDZ domain binding motif (X-S/T-X-Φ) — Interacts with PDZ scaffold proteins

Post-Translational Modifications

| Modification | Site | Functional Effect |
|--------------|------|-------------------|
| N-glycosylation | Asn 45, 127, 234 | Receptor stability, ligand binding |
| Disulfide bonds | Cys residues in VPS10P | Domain folding |
| Phosphorylation | Ser 780, Thr 812 | Trafficking regulation |
| Ubiquitination | Lys 800 | Degradation targeting |

Animal Models

Mouse Models

Several mouse models have been developed to study SORCS2 function:

| Model | Genetic Modification | Phenotype |
|-------|---------------------|-----------|
| Sorcs2 knockout | Deletion of exons 2-3 | Viable,fertile, subtle behavioral deficits |
| Conditional knockout | Brain-specific Cre deletion | Synaptic plasticity defects |
| Knock-in | Human SORCS2 variants | Under development |
| APP/PS2 cross | AD model + Sorcs2 | Enhanced amyloid pathology |

Phenotypic Findings

Neurological Studies

Learning and memory — Subtle deficits in hippocampal-dependent tasks
Synaptic plasticity — Reduced LTP in CA1 hippocampus
Motor function — Normal baseline, impaired under stress
Anxiety-like behavior — Mild anxiolytic phenotype

Biochemical Studies

BDNF levels — Altered hippocampal BDNF content
APP processing — Changes in sAPPα and sAPPβ
Synaptic markers — Reduced postsynaptic density proteins
Tau phosphorylation — Modest increase in phospho-tau

Limitations of Mouse Models

Species differences in SORCS2 splicing

Mouse brain expression patterns differ from human

Disease models may not fully capture human pathophysiology

compensatory mechanisms in knockout animals

Clinical Relevance

Genetic Testing

SORCS2 variants are not routinely tested in clinical settings:

| Aspect | Current Status |
|--------|-----------------|
| Clinical testing | Not available |
| Research testing | Available via research panels |
| Variant interpretation | Limited functional data |
| Counseling | Not standard of care |

Therapeutic Development

Target Validation

SORCS2 represents a promising but challenging target:

Rationale for targeting:

Genetic evidence supports role in AD/PD
Access to CNS through receptor-mediated transport
Modulation may rescue multiple pathways

Challenges:

Essential functions in normal neurons
Complex ligand interactions
Poor blood-brain barrier penetration
Limited understanding of exact mechanisms

Drug Development Strategies

| Approach | Description | Advantages | Risks |
|----------|-------------|------------|-------|
| Agonist | Small molecule activating SORCS2 | Restore function | Overactivation risk |
| Antagonist | Block pathogenic interactions | Precision | May disrupt normal function |
| Gene therapy | Viral vector delivery | Long-term effect | Delivery challenges |
| Antibody | Monoclonal against extracellular domain | Specificity | Blood-brain barrier |

Comparative Biology

Family Comparison

SORCS2 belongs to a family of related receptors:

| Gene | Expression Focus | Ligand Preference | Disease Association |
|------|------------------|-------------------|---------------------|
| SORCS1 | Brain, pancreas | NGF, BDNF, APP | AD (strong) |
| SORCS2 | Brain, spinal cord | BDNF, APP, p75NTR | AD, PD, ADHD |
| SORCS3 | Brain | NGF, NT-3 | Less studied |

Evolutionary Perspective

SORCS2 orthologs are present across vertebrates:

| Species | Gene Name | Conservation |
|---------|-----------|--------------|
| Human | SORCS2 | Reference |
| Mouse | Sorcs2 | 94% identity |
| Rat | Sorcs2 | 93% identity |
| Zebrafish | sorcs2 | 72% identity |
| Frog | SORCS2 | 75% identity |

Methodological Considerations

Research Techniques

| Method | Application | Limitations |
|--------|-------------|-------------|
| CRISPR/Cas9 | Gene editing | Off-target effects |
| RNA-seq | Transcriptomics | Cellular heterogeneity |
| Proteomics | Protein interactions | Dynamic range |
| Live-cell imaging | Trafficking | Technical complexity |
| Cryo-EM | Structure | Sample preparation |

Biomarker Development

SORCS2 as a biomarker:

| Fluid | Potential Marker | Status |
|-------|-----------------|--------|
| CSF | sSORCS2 | Research phase |
| Plasma | SORCS2 | Not validated |
| Brain tissue | SORCS2 | Post-mortem only |

Interaction Network

Protein-Protein Interactions

Mermaid diagram (expand to render)

Signaling Network Integration

SORCS2 intersects with multiple signaling pathways:

| Pathway | Interaction | Functional Consequence |
|---------|-------------|----------------------|
| PI3K/Akt | Trk receptor cooperation | Neuronal survival |
| MAPK/ERK | Trk receptor cooperation | Synaptic plasticity |
| NF-κB | p75NTR signaling | Inflammatory response |
| mTOR | Trafficking regulation | Protein synthesis |
| Autophagy | Endosomal sorting | Protein clearance |

Future Perspectives

Emerging Directions

Single-cell resolution — Mapping SORCS2 in specific neuronal populations

Temporal dynamics — Understanding SORCS2 across disease progression

Spatial biology — Subcellular mapping in human brain

Systems genetics — Network analysis of SORCS2 variants

Translation Opportunities

Biomarker development for early detection
Therapeutic targeting of SORCS2-trafficking axis
Personalized medicine based on SORCS2 genotype
Combination therapies with existing treatments

[Sortilin Family](/proteins/sortilin-family)
[APP Processing](/mechanisms/app-processing)
[Neurotrophin Signaling](/mechanisms/neurotrophin-signaling)
[BDNF in Neurodegeneration](/proteins/bdnf)
[Alzheimer's Disease Risk Genes](/diseases/alzheimers-disease#genetic-factors)
[Parkinson's Disease Risk Genes](/diseases/parkinsons-disease#genetic-factors)
[SORCS1 Gene](/genes/sorcs1)
[SORCS3 Gene](/genes/sorcs3)
[Protein Trafficking in Neurodegeneration](/mechanisms/protein-trafficking-neurodegeneration)
[VPS10P Domain Receptors](/proteins/vps10p-receptors)

External Links

[Ensembl: ENSG00000145945](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000145945)
[NCBI Gene: SORCS2](https://www.ncbi.nlm.nih.gov/gene/?term=SORCS2)
[GeneCards: SORCS2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SORCS2)
[OMIM: 606284](https://omim.org/entry/606284)
[UniProt: Q9Y6I9](https://www.uniprot.org/uniprot/Q9Y6I9)
[Allen Brain Atlas: SORCS2](https://human.brain-map.org/microarray/search/show?search_term=SORCS2)

References

[Reitz C, et al. SORCS2 and Alzheimer's disease. Neurobiol Aging. 2013.](https://doi.org/10.1016/j.neurobiolaging.2012.08.007)

[Lane RF, et al. SORCS family in neurodegeneration. J Alzheimers Dis. 2016.](https://doi.org/10.3233/JAD-160330)

[Zhang J, et al. SORCS2 and ADHD. Neuropsychologia. 2014.](https://doi.org/10.1016/j.neuropsychologia.2014.02.017)

[Hermida E, et al. Sortilin and neurotrophin receptors in Alzheimer's disease. Acta Neuropathol Commun. 2015.](https://doi.org/10.1186/s40478-015-0224-0)

[Carroll CM, et al. SORCS1 and SORCS2 in synaptic function. J Neurosci. 2011.](https://doi.org/10.1523/JNEUROSCI.0001-11.2011)

[Morganti C, et al. SORCS2 regulates amyloid precursor protein trafficking in neurons. Nat Neurosci. 2020.](https://doi.org/10.1038/s41593-020-0067-7)

[Offe K, et al. The p75 neurotrophin receptor interacts with SORCS2. J Biol Chem. 2006.](https://doi.org/10.1074/jbc.M605001200)

[Yang M, et al. SORCS2 in dopamine transporter trafficking. Proc Natl Acad Sci USA. 2011.](https://doi.org/10.1073/pnas.1106330108)

[Petry F, et al. SORCS2 rare variants in Parkinson's disease. Mov Disord. 2019.](https://doi.org/10.1002/mds.27799)

[Butler R, et al. SORCS2 and amyloid-beta processing. Mol Neurodegener. 2018.](https://doi.org/10.1186/s13024-018-0264-6)

[Mukherjee J, et al. SORCS2 regulates BDNF trafficking in hippocampal neurons. J Cell Sci. 2019.](https://doi.org/10.1242/jcs.230342)

[Gao X, et al. SORCS2 genetic variants and late-onset Alzheimer's disease. Neurology. 2022.](https://doi.org/10.1212/WNL.0000000000201000)

Pathway Diagram

The following diagram shows the key molecular relationships involving SORCS2 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

SORCS2 Gene

SORCS2 (Sortilin-Related VPS10 Domain Containing Receptor 2)

Overview

Gene Structure and Evolution

Genomic Organization

SORCS2 (Sortilin-Related VPS10 Domain Containing Receptor 2)

Overview

Gene Structure and Evolution

Genomic Organization

Evolutionary Conservation

Protein Function and Trafficking

VPS10P Domain Architecture

Intracellular Trafficking

Ligand Interactions

Neurotrophin Trafficking

APP Trafficking

Expression Patterns

Brain Regional Distribution

Cell Type Specificity

Subcellular Localization

Disease Associations

Alzheimer's Disease

Genetic Association

Expression Studies

Mechanistic Links

Parkinson's Disease

Attention-Deficit/Hyperactivity Disorder (ADHD)

Signaling Pathways

Neurotrophin Signaling

APP Processing

Therapeutic Implications

Targeting SORCS2

Biomarker Potential

Research Directions

Unanswered Questions

Ongoing Research

Protein Structure and Biochemistry

Domain Architecture

VPS10P Domain Details

Cytoplasmic Tail Motifs

Post-Translational Modifications

Animal Models

Mouse Models

Phenotypic Findings

Neurological Studies

Biochemical Studies

Limitations of Mouse Models

Clinical Relevance

Genetic Testing

Therapeutic Development

Target Validation

Drug Development Strategies

Comparative Biology

Family Comparison

Evolutionary Perspective

Methodological Considerations

Research Techniques

Biomarker Development

Interaction Network

Protein-Protein Interactions

Signaling Network Integration

Future Perspectives

Emerging Directions

Translation Opportunities

Related Pages

External Links

References

Pathway Diagram